share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024財年二季報
美股SEC公告 ·  2024/08/19 20:07

Moomoo AI 已提取核心訊息

FOXO Technologies reported Q2 2024 revenues of $28,000, up 133% year-over-year, primarily driven by the acquisition of Myrtle Recovery Centers on June 14, 2024. Net loss improved to $2.16 million compared to $11.29 million in Q2 2023, reflecting lower operating expenses and reduced non-operating charges. The company ended the quarter with $33,000 in cash.The company has restructured into two segments: Healthcare, comprising the newly acquired Myrtle behavioral health services, and Labs and Life, focusing on epigenetic biomarker technology. Operating expenses decreased 79% to $1.62 million, driven by lower employee costs, reduced consulting fees, and the completion of certain research projects.Management secured additional financing through various debt instruments and entered agreements to acquire RCHI's Big South Fork Medical Center. However, FOXO faces significant liquidity challenges, including defaulted Senior PIK Notes and NYSE American listing compliance issues. The company believes it can fund operations through December 2024 if the RCHI acquisition closes but requires additional capital to ensure long-term viability.
FOXO Technologies reported Q2 2024 revenues of $28,000, up 133% year-over-year, primarily driven by the acquisition of Myrtle Recovery Centers on June 14, 2024. Net loss improved to $2.16 million compared to $11.29 million in Q2 2023, reflecting lower operating expenses and reduced non-operating charges. The company ended the quarter with $33,000 in cash.The company has restructured into two segments: Healthcare, comprising the newly acquired Myrtle behavioral health services, and Labs and Life, focusing on epigenetic biomarker technology. Operating expenses decreased 79% to $1.62 million, driven by lower employee costs, reduced consulting fees, and the completion of certain research projects.Management secured additional financing through various debt instruments and entered agreements to acquire RCHI's Big South Fork Medical Center. However, FOXO faces significant liquidity challenges, including defaulted Senior PIK Notes and NYSE American listing compliance issues. The company believes it can fund operations through December 2024 if the RCHI acquisition closes but requires additional capital to ensure long-term viability.
FOXO科技報告稱2024年第二季度收入爲$28,000,同比增長133%,主要受到2024年6月14日收購Myrtle Recovery Centers的推動。淨虧損改善至$216萬,相較於2023年第二季度的$1129萬,反映出營業費用降低和非營業費用減少。公司在季度末現金餘額爲$33,000。公司已重組爲兩個部門:醫療保健部門,包括新收購的Myrtle行爲健康服務,以及實驗室與生命部門,專注於表觀遺傳生物標誌物科技。營業費用下降79%,至$162萬,主要由於員工成本降低、諮詢費用減少和某些研究項目的完成。管理層通過多種債務工具獲得了額外融資,並簽署了收購RCHI的Big South Fork醫療中心的協議。然而,FOXO面臨嚴重的流動性挑戰,包括違約的高級PIK票據和紐交所美國上市合規問題。公司相信如果RCHI收購成功,可以在2024年12月之前維持運營,但需要額外資金以確保長期可行性。
FOXO科技報告稱2024年第二季度收入爲$28,000,同比增長133%,主要受到2024年6月14日收購Myrtle Recovery Centers的推動。淨虧損改善至$216萬,相較於2023年第二季度的$1129萬,反映出營業費用降低和非營業費用減少。公司在季度末現金餘額爲$33,000。公司已重組爲兩個部門:醫療保健部門,包括新收購的Myrtle行爲健康服務,以及實驗室與生命部門,專注於表觀遺傳生物標誌物科技。營業費用下降79%,至$162萬,主要由於員工成本降低、諮詢費用減少和某些研究項目的完成。管理層通過多種債務工具獲得了額外融資,並簽署了收購RCHI的Big South Fork醫療中心的協議。然而,FOXO面臨嚴重的流動性挑戰,包括違約的高級PIK票據和紐交所美國上市合規問題。公司相信如果RCHI收購成功,可以在2024年12月之前維持運營,但需要額外資金以確保長期可行性。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息